Cost-cutting has become the norm for biopharmaceutical companies in 2023 as drug developers struggle to raise capital for ongoing research and development programs, never mind bringing in new funding for growth opportunities. But traditional reasons for restructuring are still around, as Biogen, Inc.’s round of layoffs after its acquisition of Reata Pharmaceuticals, Inc. shows.
Finance Watch: Biopharma Firms Get Ahead Of Q3 Updates With Restructuring Reveals
Infinity Files For Bankruptcy, Mallinckrodt’s Approved
Restructuring Edition: Biogen and Sana add to their layoff totals. Exscientia announced R&D program cuts while Syros, PTC, AM-Pharma, Societal CDMO, Nighthawk and Kinnate revealed layoffs to conserve cash. Also, Impel is exploring strategic options and Applied Molecular Transport will disappear in a merger with Cyclo.

More from Strategy
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.
More from Business
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.